We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Double-hit and double-expressor lymphomas

Wednesday, May 10, 2017

Sarah Rutherford, M.D., the John P. Leonard, M.D./Gwirtzman Family Research Scholar in Lymphoma, spoke to OncLive about the classification and prevalence of double-hit and double-expressor lymphomas.

Diffuse large B-cell lymphoma is the most common form of non-Hodgkin lymphoma and of all lymphomas, Rutherford explains. Though it is an aggressive disease, two-thirds of patients are able to be cured with R-CHOP chemotherapy. For the one-third of patients who are not cured, researchers have been exploring the differences of their histologies and possible therapeutic approaches.

One example is that there are chromosome changes that can occur in some of these patients, causing them to have more aggressive disease that is not as responsive to chemotherapy. The chromosome changes are called MYC and BCL-2, and when 2 of these are rearranged it is called double-hit lymphomas, she adds. Double-expressor lymphomas are not rearranged, but there is an increased expression of these chromosomes.